KLRK1 and neoplasm: The findings were consistent with those of the tumor growth inhibition study shown in Figure 6A: treatment with the NKG2D-depleting antibody abrogated the Dox plus IL-12–mediated inhibition of spontaneous metastatic tumor growth (Figure 6B).